Vulvovaginal candidiasis (VVC), or mycotic vulvovaginitis, is one of the most common vaginal infection in obstetric and gynecological practice, which is caused by Candida albicans. 70–75% of women have at least one episode of VVC during their lifetime, 45-50% - 2 times or more and 10-20% suffer from a recurrence. This infection affects not only women's health, but also significantly reduces the quality of women’s life. Clinically, vulvovaginal candidiasis symptoms include vulvar pruritus, pain, burning, erythema, and a thick discharge which are often associated with insomnia and neurosis for patients.
The mechanism of action of Zalagel® Intim is based on a unique combination of the bactericidal components of tea tree oil - terpinen-4-ol and 1,8-cineole (eucalyptol) - and a weakly alkaline pH 8-9. Tea tree oil has antifungal (on Candida albicans), antibacterial (on Gardnerella vaginalis), antiviral (on Herpes simplex), antiprotozoal (on Trichomonas vaginalis), antipruritic, anti-inflammatory and deodorizing activities. Due to its unique combination, the gel helps to reverse of vaginal discomfort: itching, burning, unpleasant odor; creates protection, preventing the migration of Candida from vulva to the vagina.
Zalagel® Intim helps to protect against infections that may appear while taking contraceptives or antibiotics, during menstruation, pregnancy, after childbirth, with vaginal dryness, urinary incontinence, cystitis, and after sexual intercourse. In addition, the gel helps to prevent recurrent infections. Zalagel® Intim indicated for combination with an antifungal medication that can increase the comfort of the therapy.
“Egis strives to make available modern European developments for all Russian patients. We hope that our new Zalagel® Intim will help maintain the intimate health of Russian women, making their lives better, ”says Olga Gultikova, Medical Director of EGIS-RUS LLC.